Beyond the R² horizon: new triplet regimens for relapsed and/or refractory follicular lymphoma

Key Points

• Improved outcomes observed with triplet regimens for relapsed and/or refractory follicular lymphoma, indicating enhanced effectiveness.
• The analysis highlights a notable survival rate increase, with up to 65% of patients responding positively.
• Assessment using clinical data across multiple centers shows significant improvement in treatment responses.
• Supports the transition to triplet treatments for better management options; requires further validation in larger studies.